Beam Therapeutics Inc. research snapshot
BEAM AI stock analysis currently reads Beam Therapeutics Inc. as a pioneering precision genetic medicine company built on its proprietary base editing platform, which can make single-nucleotide changes in DNA without double-strand breaks. The stock closed at $32.68 on July 10, 2026, implying about $3.36 billion of equity value using 102.88 million shares. The company holds $1.21 billion in cash against $250.82 million in total debt, providing multi-year runway, but generated TTM revenue of approximately $164 million (primarily collaboration revenue) with a TTM net loss of roughly $66 million. Recent news includes an adverse arbitration ruling in the patent dispute with Prime Medicine, FDA clearance of BEAM-304 IND for PKU, and a BofA reiterated Buy rating with a $47 target. The main debate is whether the base editing pipeline can deliver clinical proof-of-concept, whether the Prime Medicine dispute limits the platform, and whether the stock can overcome its 23% short interest. This page is informational research and is not investment advice.
Current price
$32.68 close on July 10, 2026
Market cap
$3.36 billion using 102.88 million shares; price times shares verified with 0.00% variance
AI score
42 / 100
Rating
Pioneering base editing platform with a broad pipeline and key partnerships, offset by pre-profitability, significant cash burn, 23% short interest, recent adverse patent arbitration ruling, and binary clinical outcomes
Trend status
Price at $32.68 is above the 50-day moving average near $31.50 but below the recent high of $37.92; YTD return of about 18% with high volatility and beta near 2.18
Data cutoff (updated monthly)
July 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Beam Therapeutics develops precision genetic medicines using its proprietary base editing platform, which can make targeted single-nucleotide changes in DNA. Unlike traditional CRISPR/Cas9, base editing does not create double-strand breaks. The pipeline spans ex vivo HSC therapies for sickle cell disease and beta-thalassemia, in vivo liver-directed programs for AATD, PKU, and GSD1a, and the ESCAPE platform for antibody-based conditioning. | Medium |
| Moat | The moat comes from foundational base editing intellectual property pioneered by David Liu and the Broad Institute, deep scientific expertise, first-mover status in base editing technology, and strategic partnerships with Pfizer, Verve, and Orbital. However, the recent adverse arbitration ruling with Prime Medicine over certain patent rights creates uncertainty, and competing platforms (CRISPR/Cas9, prime editing, other base editing variants) pose competitive pressure. | Medium |
| Management | CEO John M. Evans, MBA, leads BEAM and previously served in senior leadership roles at other biotech companies. Co-founder David R. Liu serves on the scientific advisory board. Management has secured significant partnerships and advanced multiple pipeline programs. However, insider selling of about $10 million in the past three months is a concern, and the key test remains clinical execution and capital allocation discipline as cash burn continues. | Medium |
| Financial trend | The company is pre-profit with TTM revenue of about $164 million (largely collaboration revenue) and a TTM net loss of approximately $66 million. Operating cash burn was roughly $370 million TTM. The $1.21 billion cash position provides runway, but continued losses mean the company may eventually need to raise additional capital or achieve profitability. | High |
| Valuation | At $32.68, the stock trades at a market cap of $3.36 billion. With negative GAAP earnings, traditional P/E is not applicable. Enterprise value of about $2.40 billion (market cap minus net cash of roughly $960 million) prices in pipeline optionality. The stock trades at about 2.68x book value and 20.47x TTM revenue. The $46.85 consensus analyst price target suggests about 43% upside from the current price. | Medium |
| Technical trend | Price at $32.68 is above the 50-day moving average but below the 200-day average. The 52-week range is $15.60 to $38.26. Beta near 2.18 indicates very high volatility. YTD return is about 18%, and the stock trades 17.9% above the start of the year. | Medium |
| Risk level | Risk is high. Pre-profitability, binary clinical outcomes, recent adverse patent arbitration ruling, elevated cash burn, 23% short interest, very high beta of 2.18, insider selling, and competitive pressure from gene-editing platforms all contribute. Dilution risk exists as the company may need to raise capital. | High |
| AI confidence | Data confidence is high for balance sheet items, share count, and market-cap verification, but lower for pipeline probability-adjusted valuation, BEAM-302 and BEAM-304 peak sales estimates, and long-term price scenarios. | Medium data confidence |
| Investment certainty | Investment certainty is low to medium. BEAM has a differentiated base editing platform and a deep pipeline with multiple catalysts expected, but the company is not yet profitable, the Prime Medicine patent dispute has created uncertainty, clinical and commercial execution is unproven, and the stock carries high volatility that may not suit all investors. | Low to medium |
BEAM AI stock forecast
The BEAM AI stock forecast uses a scenario framework around the $32.68 cutoff price. Because BEAM has negative EPS, traditional P/E-based scenario models are not applicable. The scenarios below are qualitative framework estimates based on pipeline progress, partnership developments, clinical data readouts, cash position, and analyst consensus, not promises or recommendations.
$55 to $80
More likely if BEAM-302 and BEAM-304 show positive clinical data, the Prime Medicine dispute is resolved favorably through licensing, the ESCAPE platform advances, partnership milestones from Pfizer or Verve materialize, and short interest decreases. HC Wainwright has an $80 target and several analysts see significant upside.
$30 to $50
More likely if pipeline candidates advance without major surprises, the Prime Medicine dispute requires licensing payments that are manageable, cash burn remains under control, and the stock trades in line with the $46.85 consensus analyst target with normal biotech volatility.
$15 to $28
More likely if the Prime Medicine patent dispute results in significant restrictions or royalties, clinical trials disappoint, competition from CRISPR/Cas9 and prime editing platforms intensifies, cash burn accelerates requiring dilutive financing, or the stock is pressured by sustained short interest and insider selling.
BEAM AI technical analysis
BEAM AI technical analysis uses public market data available at the July 12, 2026 cutoff. The latest public close was $32.68 on July 10, 2026. MarketBeat reported a 50-day moving average, a 52-week range of $15.60 to $38.26, and beta near 2.18. Technical levels describe market structure and do not predict the next price move.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $32.68 | Latest public close used for this page, dated July 10, 2026. |
| Near support | $26 to $30 | The 50-day moving average and the recent trading range form the first support band. |
| Key support | $15.60 | The 52-week low is a critical support level. A break below this would indicate significant technical weakness. |
| Near resistance | $35 to $38 | The recent high near $37.92 and the upper end of the 50-day range create the first overhead resistance zone. |
| Key resistance | $38.26 | The 52-week high is the next major reference point if price reclaims the $38+ zone. |
| 50-day moving average | About $31.50 | Price above this average indicates short-term trend support as of the July 10, 2026 data snapshot. |
| Momentum | RSI near neutral territory | RSI was neither overbought nor oversold in mid-2026, indicating no clear directional signal from momentum alone. |
| Volume | About 2.83 million shares on July 10, 2026 | Daily volume was above the 2.47 million average, suggesting elevated interest on the down day. |
| Volatility | 52-week range $15.60 to $38.26; beta near 2.18 | The wide annual range and very high beta make position sizing and predefined risk limits essential for any trading framework. |
| Invalidation | A sustained close below $24 | A decisive break below the recent support zone would invalidate the constructive technical setup and suggest further downside risk. |
BEAM AI trading strategy
The BEAM AI trading strategy is a rules-based framework, not personalized advice. Pair price action with pipeline clinical data readouts, partnership announcements, patent dispute developments, cash runway updates, analyst ratings, and short interest trends.
Consider a trend-following framework only after price reclaims and holds above the $35 to $38 resistance zone, confirmed by above-average volume, positive clinical data readouts, or favorable partnership developments.
A close back below the 50-day average near $31.50 reduces confidence. A sustained close below the 52-week low at $15.60 invalidates the setup.
If price tests the $26 to $30 support zone while the company maintains its cash position and clinical pipeline remains on track, the risk/reward may favor a mean-reversion framework. However, biotech mean-reversion carries binary gap-down risk on negative news.
Do not average down automatically if the Prime Medicine dispute escalates, cash burn accelerates, clinical trials fail, or partnership agreements are terminated. Biotech stocks can gap down significantly on binary news events.
Track BEAM-302 and BEAM-304 clinical data readouts, the Prime Medicine patent dispute resolution, Pfizer and Verve partnership updates, FDA IND clearances, cash runway, and short interest changes. Major events can produce outsized moves given the 2.18 beta.
Reduce position size before binary clinical data events or patent ruling announcements. A failed trial or adverse patent ruling can destroy 30-50% of market value overnight.
Investment research summary
Beam Therapeutics sells precision genetic medicines built on its proprietary base editing technology, which makes single-nucleotide changes in DNA without double-strand breaks. Customers are patients with serious genetic diseases. The company is paid through partnership collaboration revenue and potential future product revenues. The business model is high-risk, high-reward biotech drug development.
The moat rests on foundational base editing IP pioneered by David Liu, first-mover advantage in base editing, and strategic partnerships with Pfizer, Verve, and Orbital. However, the recent adverse arbitration ruling with Prime Medicine creates patent uncertainty, and competing platforms (CRISPR/Cas9, prime editing) create competitive pressure.
The thesis fails if the Prime Medicine patent dispute restricts BEAMs freedom to operate or imposes significant royalty costs. Pipeline candidates BEAM-302 (AATD), BEAM-304 (PKU), or BEAM-101 (sickle cell) could fail in clinical trials. Cash burn could require dilutive financing. Pfizer or Verve could deprioritize partnerships. Competitors with superior editing technologies could leapfrog base editing.
CEO John M. Evans has led the company and brings biotech leadership experience. Co-founder David R. Liu provides scientific vision. Management has secured key partnerships and advanced a broad pipeline. The key test is clinical execution and capital allocation as the company transitions from platform development to clinical-stage biotech. Insider selling of approximately $10 million in recent months is worth monitoring.
Precision gene editing represents a potential paradigm shift in medicine. Base editing, as a more precise alternative to traditional CRISPR/Cas9, is at the forefront of next-generation gene editing. The field has attracted significant investment, partnerships, and scientific talent. However, intense competition and rapid technological change mean no platform has a guaranteed lead.
At $32.68, BEAM trades at a $3.36 billion market cap with negative earnings. The enterprise value of about $2.40 billion (net of $960 million in net cash) prices in pipeline optionality. Margin of safety is limited given pre-profitability, binary risks, 23% short interest, and the unresolved Prime Medicine patent dispute. The $46.85 consensus analyst target suggests upside, but downside to $15-28 is possible in a bear scenario.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $32.68 close on July 10, 2026 | MarketBeat | July 12, 2026 |
| Shares outstanding | 102.88 million shares | MarketBeat and Motley Fool | July 12, 2026 |
| Market capitalization | $3.36 billion computed from $32.68 x 102.88 million shares | Financial rigor market-cap verification | July 12, 2026 |
| TTM revenue and net income | $164.01 million revenue and -$65.98 million GAAP net income (TTM, Yahoo Finance) | Yahoo Finance and Motley Fool | July 12, 2026 |
| Cash and total debt | $1.21 billion cash/ST investments and $250.82 million total debt | Yahoo Finance, Motley Fool, MarketBeat (cross-verified) | July 12, 2026 |
| Enterprise value | About $2.40 billion (market cap minus net cash) | Computed from reported cash and debt figures | July 12, 2026 |
| TTM EPS | -$0.68 per share | MarketBeat | July 12, 2026 |
| Price-to-book ratio | 2.68x | MarketBeat | July 12, 2026 |
| Price-to-sales ratio | 20.47x (TTM) | Yahoo Finance | July 12, 2026 |
| Technical snapshot | 50-day average about $31.50, 52-week range $15.60 to $38.26, beta 2.18 | MarketBeat statistics | July 12, 2026 |
| Short interest | 23.12% of float; 8.38 days to cover | MarketBeat | July 12, 2026 |
| Consensus analyst rating | Moderate Buy with $46.85 average price target (15 analysts) | MarketBeat | July 12, 2026 |
| Q1 2026 earnings | Revenue $31.74 million (up 324.9% YoY); EPS -$0.91 (beat -$1.03 estimate) | MarketBeat and Motley Fool | July 12, 2026 |
| Prime Medicine patent dispute | Adverse arbitration ruling for BEAM in July 2026; Prime Medicine claimed victory | Seeking Alpha, MarketWatch, Boston Globe | July 12, 2026 |
| CEO | John M. Evans, MBA (CEO) | MarketBeat and Beam Therapeutics website | July 12, 2026 |
This BEAM page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are conditional scenarios based on available data and assumptions. Biotech investments carry high risk, including binary clinical outcomes, patent litigation uncertainty, regulatory risk, and potential capital dilution. Data can be delayed, incomplete, or wrong. Verify all information from original filings and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
